Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abbott Laboratories
(NY:
ABT
)
107.53
+0.67 (+0.63%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Abbott Laboratories
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
29
30
Next >
Looking At Abbott Laboratories's Recent Unusual Options Activity
July 20, 2023
Via
Benzinga
Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript
July 20, 2023
ABT earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Tesla Recalls Over 17K EVs Over Camera & Seat Belt Issues, University Research Uncovers Unexpected Fluctuations In ChatGPT Capabilities, Juul Seeks FDA Nod For Next-Generation Vaporizer: Today's Top Stories
July 20, 2023
Benzinga Tesla Recalls More Than 17,000 EVs Over Camera, Seat Belt Issues
Via
Benzinga
Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook
July 20, 2023
Abbott Laboratories (NYSE: ABT) has reported Q2 FY23 adjusted EPS of $1.08, down 25% Y/Y, beating the consensus of $1.05.
Via
Benzinga
Abbott Stock Edges Higher As Earnings Decline But Still Top Forecasts
July 20, 2023
The company continues to expect some Covid sales this year, but cut its outlook.
Via
Investor's Business Daily
Abbott Laboratories's Earnings Outlook
July 19, 2023
Via
Benzinga
What's In Store For Abbott Laboratories In Q2 Earnings?
July 15, 2023
Abbott Laboratories is slated to report second-quarter 2023 results on July 20 before the market opens.
Via
Talk Markets
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
July 10, 2023
Via
Benzinga
Earnings Scheduled For July 20, 2023
July 20, 2023
Companies Reporting Before The Bell • Taiwan Semiconductor (NYSE:TSM) is estimated to report quarterly earnings at $1.08 per share on revenue of $15.49 billion.
Via
Benzinga
Johnson & Johnson, Tesla And 3 Stocks To Watch Heading Into Thursday
July 20, 2023
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
July 03, 2023
Via
Benzinga
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
June 23, 2023
Via
Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
June 20, 2023
Via
Benzinga
Markets Remain Bullish After Dow Rises For Eighth Consecutive Session
July 20, 2023
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Wednesday. The Dow Jones gained recorded gains for the eighth straight session on Wednesday, its longest winning streak since...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 06, 2023
Via
Benzinga
Abbott Scores FDA Nod For First Dual-Chamber Leadless Pacemaker To Treat Abnormal, Slow Heart Rhythms
July 05, 2023
The FDA has approved Abbott Laboratories' (NYSE: ABT) AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system to treat
Via
Benzinga
GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations
June 27, 2023
Morgan Stanley analyst Patrick Wood initiated coverage on GE HealthCare Technologies Inc (NASDAQ: GEHC) with an Equal-Weight rating and a
Via
Benzinga
Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market
June 23, 2023
The company makes continuous glucose monitors for patients with diabetes.
Via
Investor's Business Daily
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
June 16, 2023
Via
Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
June 06, 2023
Via
Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
May 23, 2023
Via
Benzinga
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval
June 20, 2023
The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device
Via
Benzinga
3 Passive Income Stocks to Hold for the Next 20 Years
June 20, 2023
These three stocks are likely to keep increasing their dividends over years or even decades.
Via
The Motley Fool
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application
June 13, 2023
In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte
Via
Benzinga
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
June 04, 2023
Recent troubles won't stop these companies' long-term trajectories.
Via
The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
June 01, 2023
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...
Via
Benzinga
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories
May 24, 2023
Benzinga
Via
Benzinga
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
May 24, 2023
Via
Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
May 24, 2023
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne
Via
Benzinga
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
May 23, 2023
U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.